Should You Buy Reliance Inc (RS) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
332.290
1 Day change
1.97%
52 Week Range
347.440
Analysis Updated At
2026/01/26
Reliance Inc (RS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show bullish momentum, the stock is overbought (RSI at 80.706) and may face short-term corrections. Additionally, mixed analyst ratings, declining financial performance, and lack of significant positive catalysts do not support an immediate buy decision.
Technical Analysis
The stock is currently in a bullish trend with SMA_5 > SMA_20 > SMA_200, and MACD is positive. However, RSI at 80.706 indicates the stock is overbought, suggesting potential short-term corrections. Key resistance levels are at R1: 330.861 and R2: 337.495, with support levels at S1: 309.385 and S2: 302.751.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
2
Buy
11
Positive Catalysts
Bullish moving averages and a positive MACD histogram also suggest upward momentum.
Neutral/Negative Catalysts
The RSI indicates the stock is overbought, and financial performance in Q3 2025 showed declines in net income (-4.87% YoY), EPS (-0.55% YoY), and gross margin (-4.01% YoY). Analysts have mixed ratings, with some lowering price targets. No significant news or congress trading data to act as a positive catalyst.
Financial Performance
In Q3 2025, revenue increased by 6.75% YoY to $3.65B, but net income dropped by 4.87% YoY to $189.5M. EPS also declined slightly by 0.55% YoY to 3.59, and gross margin dropped to 26.34%, down 4.01% YoY.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts have mixed views. KeyBanc raised the price target to $325, while JPMorgan and BofA lowered their targets to $340 and $305, respectively. Ratings range from Overweight to Neutral, reflecting uncertainty in the stock's near-term potential.
Wall Street analysts forecast RS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RS is 314.5 USD with a low forecast of 284 USD and a high forecast of 340 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast RS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RS is 314.5 USD with a low forecast of 284 USD and a high forecast of 340 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 325.860
Low
284
Averages
314.5
High
340
Current: 325.860
Low
284
Averages
314.5
High
340
KeyBanc
Overweight
maintain
$320 -> $325
AI Analysis
2026-01-07
Reason
KeyBanc
Price Target
$320 -> $325
AI Analysis
2026-01-07
maintain
Overweight
Reason
KeyBanc raised the firm's price target on Reliance to $325 from $320 and keeps an Overweight rating on the shares. The firm is refreshing its 2026 outlook on U.S. carbon steel equities post recent due diligence and completion of its Q4 2025 proprietary Sheet on the Street survey. KeyBanc estimate changes for Q4 2025 on sheet mills are subdued amid trough lag pricing and outages. The firm's 2026 revisions are mixed-to-positive, supportive of a nicely improved year of profitability for the sector.
Morgan Stanley
Equal Weight -> Overweight
upgrade
£790
2026-01-06
Reason
Morgan Stanley
Price Target
£790
2026-01-06
upgrade
Equal Weight -> Overweight
Reason
Morgan Stanley upgraded RS Group to Overweight from Equal Weight with an unchanged price target of 790 GBp. The firm adjusted rating in the European business services group as part of its 2026 outlook. The analyst is cautious on the staffers and chemical distribution. Morgan Stanley's preferred stocks for 2026 are Experian, Diploma, Rentokil, Verisure, Bureau Veritas and ISS.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RS
